Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS COMPASS Pathways	$2.76 +9.1%	$4.06	$2.25 ▼ $8.54	$236.71M	2.25	1.15 million shs	7.85 million shs
GPCR Structure Therapeutics	$21.79 -2.6%	$23.46	$13.22 ▼ $47.48	$1.28B	-1.87	846,714 shs	704,601 shs
OCUL Ocular Therapeutix	$9.19 +1.1%	$7.96	$5.79 ▼ $11.78	$1.45B	1.42	1.42 million shs	2.90 million shs
SPRY ARS Pharmaceuticals	$17.26 +2.9%	$14.50	$7.66 ▼ $18.51	$1.65B	0.84	1.32 million shs	1.40 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS COMPASS Pathways	+7.66%	-43.53%	-41.97%	-15.10%	-59.78%
GPCR Structure Therapeutics	+1.27%	+6.72%	-8.84%	+11.90%	-48.76%
OCUL Ocular Therapeutix	+8.60%	+9.52%	+24.52%	+18.51%	+39.20%
SPRY ARS Pharmaceuticals	+1.27%	+13.23%	+12.02%	+33.17%	+103.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPS COMPASS Pathways	2.1923 of 5 stars	3.4	3.0	0.0	1.7	0.8	0.6
GPCR Structure Therapeutics	2.2738 of 5 stars	3.5	2.0	0.0	1.9	1.7	0.6
OCUL Ocular Therapeutix	3.695 of 5 stars	3.5	1.0	4.1	2.1	2.5	0.0
SPRY ARS Pharmaceuticals	3.2407 of 5 stars	3.6	2.0	0.0	2.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	515.94% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	249.55% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.33	88.61% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	79.61% Upside

Current Analyst Ratings Breakdown

Latest CMPS, SPRY, GPCR, and OCUL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
OCUL Ocular Therapeutix	$63.72M	22.98	N/A	N/A	$2.01 per share	4.57
SPRY ARS Pharmaceuticals	$89.15M	19.01	$0.01 per share	1,981.51	$2.64 per share	6.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)

Latest CMPS, SPRY, GPCR, and OCUL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS COMPASS Pathways	0.11	10.18	10.18
GPCR Structure Therapeutics	N/A	23.29	23.29
OCUL Ocular Therapeutix	0.26	10.22	10.14
SPRY ARS Pharmaceuticals	0.30	11.00	10.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS COMPASS Pathways	46.19%
GPCR Structure Therapeutics	91.78%
OCUL Ocular Therapeutix	59.21%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
CMPS COMPASS Pathways	3.93%
GPCR Structure Therapeutics	9.43%
OCUL Ocular Therapeutix	2.30%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable

CMPS, SPRY, GPCR, and OCUL Headlines

Recent News About These Companies

Q2 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst

June 25 at 6:12 AM | marketbeat.com

Harbour Capital Advisors LLC Purchases New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 25 at 5:27 AM | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by AssuredPartners Investment Advisors LLC

June 25 at 5:02 AM | marketbeat.com

What is Leerink Partnrs' Estimate for SPRY FY2029 Earnings?

June 25 at 2:54 AM | americanbankingnews.com

Brokers Offer Predictions for SPRY FY2029 Earnings

June 24 at 6:39 AM | marketbeat.com

Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $240,000.00 in Stock

June 23 at 4:25 AM | americanbankingnews.com

Janney Montgomery Scott LLC Boosts Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 23 at 3:28 AM | marketbeat.com

Eric Karas Sells 15,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

June 20, 2025 | marketbeat.com

249,230 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Advisor Resource Council

June 20, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Average Target Price from Brokerages

June 19, 2025 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

June 16, 2025 | marketbeat.com

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

June 15, 2025 | msn.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Still a Buy?

June 13, 2025 | marketbeat.com

Cantor Fitzgerald Estimates SPRY FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Sells 115,987 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 6, 2025 | marketbeat.com

Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 5, 2025 | marketbeat.com

Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 3, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3% - Here's Why

May 31, 2025 | marketbeat.com

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

May 27, 2025 | globenewswire.com

Millennium Management LLC Acquires 452,532 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

May 26, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 Shares

May 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, SPRY, GPCR, and OCUL Company Descriptions

COMPASS Pathways NASDAQ:CMPS

$2.76 +0.23 (+9.09%)

Closing price 04:00 PM Eastern

Extended Trading

$2.72 -0.03 (-1.27%)

As of 07:59 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Structure Therapeutics NASDAQ:GPCR

$21.79 -0.59 (-2.64%)

Closing price 04:00 PM Eastern

Extended Trading

$21.84 +0.05 (+0.21%)

As of 07:58 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$9.19 +0.10 (+1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$9.18 0.00 (-0.05%)

As of 07:45 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$17.26 +0.48 (+2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$17.04 -0.22 (-1.27%)

As of 07:58 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time